



G Medical Innovations Holdings Ltd
ARBN 617 204 743

ASX Announcement

27 July 2020

13 more US university hospitals complete Evaluation phase of GMV's Independent Diagnostic Testing Facilities (IDTF) platform - 2 more already deploying the service

- **Two more university hospitals have deployed IDTF – takes the total to six – with active patient enrolments and treatment ongoing and increasing**
- **11 additional university hospitals have now completed the *Evaluation* Phase and commencing Implementation**
- **Deployment by hospitals undertaken in three phases - *Evaluation, Implementation and Treatment***
- **GMV receives ~US\$175 to ~US\$750 in reimbursements per patient monitored depending on specific modality**
- **More university hospitals to be added - aggressive US business development program in US now paying off**

Medical device, Telehealth and Medical Services company **G Medical Innovations (ASX: GMV) (“G Medical” or the “Company”)** is pleased update shareholders on the continuing expansion of its Independent Diagnostic Testing Facilities (IDTF) platform and remote patient monitoring services in the United States as more hospitals associated with leading universities deploy and evaluate the service.

On 16 July, G Medical reported that the first four US university hospitals had deployed the IDTF platform with ~2,000 patients already enrolled and undergoing treatment. Today, we are delighted to report that our wholly owned subsidiary, G Medical Diagnostic Services Inc. (GMEDx), has secured two more university hospital deployments for IDTF with patients now being enrolled. Current numbers are still to be determined shortly and will be added to the first ~2,000 reported. More noteworthy is the fact that 11 more university hospitals have now completed the ***Evaluation*** phase and will commence ***Implementation*** and patient enrolments from August and throughout Q3. This totals 17 Hospital partners for G Medical to date in various stages of IDTF commercialisation.

To give shareholders a greater understanding of the IDTF platform, GMEDx has delineated a three-phase approach to onboard new hospitals: ***Evaluation, Implementation and Treatment*** phases (*refer table overleaf*).

G Medical expects to receive between ~US\$175 and ~US\$750 per patient monitored via reimbursements from insurers (i.e.: Medicare), with the variance based on the specific modality and duration, including; AECG patch, Mobile Cardiac Telemetry (MCT), Cardiac Event Monitoring (CEM). Additional revenue can be earned from potential sales channel for G Medical's FDA approved Prizma and GMP “Patch” device.

As advised, IDTF is the core infrastructure of G Medical's patient and medical services to supports its medical device and telehealth technology offerings, and has been a dependable and predictable revenue contributor for G Medical. Based on sales and business development efforts, the Company is forecasting a three-fold increase in patient monitoring numbers by the end of CY2020 (CY2019: 27,946 patients monitored).

While the ongoing business development and R&D programmes continue to be formulated and adopted, and the Company scales up operations and increases market share, the names of new hospital deployments remain commercial in confidence at this time.

G Medical's CEO Dr Yacov Geva, commented: *"Deployment of the IDTF platform into the United States hospital sector is now steadily building, and as patient monitoring commences, this will be reflected in future reported revenue. This will materialise from August onwards as patients are onboarded and complete their personalised treatment modalities, and we are confident of meeting our stated goal of growing patient monitoring numbers three-fold this calendar year.*

"The three phases of deployment we are illustrating today provides shareholders with greater transparency around how we are growing IDTF and the steps involved in establishing institutional partners and onboarding patients. This way, we will be able to clearly map and report hospital and patient numbers in the various phases.

"We stress that we are putting in place the foundations for a major scale up of IDTF throughout the US hospital network and our success with university hospitals is only just the beginning. We look forward to updating shareholders on more hospital deployments and patient enrolments very soon. Patient enrolments is the key benchmark here and that is what we are focused on building by providing reliable and dependable telehealth services to these hospitals."

Three phase approach to IDTF platform deployment with United States university hospitals:

Evaluation:	Implementation:	Treatment:
<ul style="list-style-type: none"> ▪ Identify university hospitals and medical institutions that institutions that would benefit from cardiac monitoring technologies and services, provided through G Medical’s IDTF operations. ▪ Commence discussions with a number of management personnel at a number of hospitals is ongoing. ▪ Demonstrations of G Medical’s IDTF platform and medical devices with management, institutional physicians and staff. ▪ Decision is made by hospital management to implement G Medical’s IDTF platform. 	<ul style="list-style-type: none"> ▪ Ongoing education, training, and support services for institutional physicians and staff. ▪ Cyber security protocols and implementation in conjunction with in-hospital IT departments. ▪ Implementation of G Medical’s ‘applications’ into organisation mainframes. ▪ G Medical’s ‘Home Connect’ set-up and deployment. ▪ Data management, diagnostic and related protocols. ▪ Patient selection, enrolment, medical device deployment and management protocols set. 	<ul style="list-style-type: none"> ▪ Patient enrolments commence from hospital and individualised monitoring service (24 hours to 30 days or longer) commences. ▪ G Medical to receive between US\$[value] and US\$[Value] per patient monitored, plus a daily service fee – revenue to be booked within 90 days of enrolment. ▪ Services can include Mobile Cardiac Telemetry (MCT), Holter Monitoring and Ambulatory electrocardiography (AECG). ▪ Deployment allows for improved revenue for partner hospital and better patient care. ▪ R&D and business development work continues to broaden service offering, enhance protocols, improve efficiency and expand hospital staff knowledge base. <ul style="list-style-type: none"> ○ Build sustainable infrastructure within Institutional partners; ○ Medical device inventory management; ○ Broadened direct and remote patient monitoring services; ○ Improved cardiac rhythm disturbance protocols; ○ Improved protocols for the placement of ‘Cardiac Event Monitors’ post Transcatheter aortic valve replacement (TAVR), and other procedures.

Ends

Authorised for release by Yacov Geva, Managing Director.

Released through: Henry Jordan, Six Degrees Investor Relations: +61 (0) 431 271 538

About G Medical Innovations

G Medical (**ASX: GMV**) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and e-health solutions using its suite of proprietary devices and software solutions, as well as patient service operations, with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit www.gmedinnovations.com

About G Medical products:

G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals.

The 'Prizma' Medical Smartphone Case is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The 'Prizma' allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members.

G Medical also offers a professional real-time patient continuous monitoring solution, G Medical's Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge home-based settings.